

AMENDMENTS TO THE CLAIMS:

This listing will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. – 30. (Canceled)

31. (Previously Presented) A method for augmenting vaccinations in a host comprising:

administering to said host a peptide having the formula R'-Glx-Lys-R" or a pharmaceutically acceptable salt thereof,

wherein Glx is Glu or Gin; R' is LI- or a first amino acid sequence having 7 or fewer amino acids;

wherein R" is —H or a second amino acid sequence having fewer than 7 amino acids;

wherein said peptide has a sequence of at least 2 but not more than 9 amino acids; and

administering to said host a vaccine.

32. (Previously Presented) The method of claim 31, wherein said peptide having the formula R'-GlxLys-R" or a pharmaceutically acceptable salt thereof is administered simultaneously with said vaccine.

33. (Previously Presented) The method of claim 31, wherein said peptide having the formula R'-GlxLys-R" or a pharmaceutically acceptable salt thereof is administered prior to the administration of said vaccine.

34. (Previously Presented) The method of claim 31, wherein said peptide having the formula R'-GlxLys-R" or a pharmaceutically acceptable salt thereof is administered after the administration of said vaccine.

35. (Currently Amended) The method of claim 31, wherein R' is H-, Glx-, Thr-Ala-Glx-, Tbr-ProGlx-, Ser-Ala-Glx-, Ser-Pro-Glx-, Ser-Ser-Glx-, Met-Leu-Thr-Ala-Glx- [SEQ ID NO:4], or Leu-Thr-Ala-Glx- [SEQ ID NO:5]; and R" is -H, -Ala, -Ala-Ala or -Ala-Val.

36. (Currently Amended) The method of claim 31, wherein said peptide having the formula R'-GlxLys-R" or a pharmaceutically acceptable salt thereof is selected from the group consisting of: Thr-Ala-Glu-Glu-Lys [SEQ ID NO:3], Tbr-Ala-Gln-Gln-Lys, and Glu-Lys.

37. (Previously Presented) The method of claim 31, wherein R" is -H.

38. (Currently Amended) The method of claim 31, wherein said peptide having the formula R'-GlxLys-R" or a pharmaceutically acceptable salt thereof is selected from the group consisting of: Thr-Pro-Glu-Glu-Lys [SEQ ID NO:2], Thr-Pro-Gln-Gln-Lys, and Thr-Pro-Glx-Glx-Lys.

39. (Currently Amended) The method of claim 31, wherein said peptide having the formula R'-GlxLys-R" or a ~~phannaceutically~~ pharmaceutically acceptable salt thereof is selected from the group consisting of: Leu-Thr-Ala-Glx-Glx-Lys-Ala, Leu-Thr-Ala-Glx-Glx-Lys-Ala-Ala, and Leu-Thr-Ala-Glx-GlxLys-Ala-Val.

40. (Currently Amended) The method of claim 31, wherein said peptide having the formula R'-GlxLys-R" or a pharmaceutically acceptable salt thereof is in combination with a pharmaceutically acceptable carrier ~~is administered as a pharmaceutical composition.~~

41. (Currently Amended) The method of claim 40, wherein said pharmaceutical composition comprises said peptide having the formula R'-Glx-Lys-R" or a pharmaceutically acceptable salt thereof in an amount of 0.001% to 20% by weight and a pharmaceutically acceptable ~~carmer~~ carrier.

42. (Previously Presented) The method of claim 41, wherein said pharmaceutically acceptable carrier is an aqueous solution.

43. (Previously Presented) The method of claim 41, wherein said pharmaceutically acceptable carrier comprises a buffer selected from sodium acetate, sodium lactate, sodium chloride, potassium chloride and calcium chloride.

44. (Previously Presented) The method of claim 41, wherein said pharmaceutical composition comprises 0.1 mg of the peptide.

45. (Previously Presented) The method of claim 31, wherein said peptide having the formula R'-GlxLys-R" or a pharmaceutically acceptable salt thereof is administered parenterally.

46. (Previously Presented) The method of claim 31, wherein said peptide having the formula R'-GlxLys-R" or a pharmaceutically acceptable salt thereof is administered orally.

47. (Previously Presented) The method of claim 31, wherein said peptide having the formula R'-GlxLys-R" or a pharmaceutically acceptable salt thereof is administered intranasally, intravenously or intramuscularly.